Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Bay 59-3074 is a novel, potent, orally active and selective cannabinoid CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively. BAY-59-3074 may have analgesic effects. In rat models of chronic neuropathic and inflammatory pain, it demonstrates anti-hyperalgesic and antiallodynic properties. The conclusion is that BAY 59-3074 might provide a useful therapeutic strategy for the management of various chronic pain conditions.
Targets |
human CB2 receptor ( Ki = 45.5 nM ); human CB1 receptor ( Ki = 48.3 nM ); rat CB1 receptor ( Ki = 55.4 nM )
|
---|---|
ln Vivo |
BAY 59-3074 (oral administration; 0.3–3 mg/kg; daily; for 2 weeks; male Wistar rats) Rat models of chronic neuropathic and inflammatory pain show improved antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli with treatment.
|
Animal Protocol |
Male Wistar rats (160-250 g)
0.3 mg/kg, 1 mg/kg, and 3 mg/kg Oral administration; daily; for 2 weeks. |
References |
Molecular Formula |
C18H13NO4F6S
|
---|---|
Molecular Weight |
453.35552
|
Exact Mass |
420.18
|
Elemental Analysis |
C, 59.99; H, 5.03; F, 4.52; N, 26.65; O, 3.81
|
CAS # |
406205-74-1
|
Appearance |
Solid powder
|
SMILES |
C1=CC(=CC(=C1)OS(=O)(=O)CCCC(F)(F)F)OC2=CC=CC(=C2C#N)C(F)(F)F
|
InChi Key |
LWUSZIVDPJPVBW-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C18H13F6NO4S/c19-17(20,21)8-3-9-30(26,27)29-13-5-1-4-12(10-13)28-16-7-2-6-15(14(16)11-25)18(22,23)24/h1-2,4-7,10H,3,8-9H2
|
Chemical Name |
[3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl] 4,4,4-trifluorobutane-1-sulfonate
|
Synonyms |
BAY59-3074; BAY-593074; BAY-59-3074; BAY 59-3074; BAY 593074; BAY593074
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~91 mg/mL (~200.7 mM)
Ethanol: ~91 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2058 mL | 11.0288 mL | 22.0575 mL | |
5 mM | 0.4412 mL | 2.2058 mL | 4.4115 mL | |
10 mM | 0.2206 mL | 1.1029 mL | 2.2058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.